Tirzepatide represents a major shift in metabolic science, having received its first major FDA approval in May 2022
When compared to IVY RX and other providers like LifeMD and ReflexMD, RemedyMeds excels in transparency and personalized patient support, although some might argue that their medication range is still evolving
Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness
Orth said his team plans to evaluate next steps later this year or early next year, including whether it will step into the public markets
Well outline the structured clinical oversight and safety netting necessary to ensure your journey toward a 21% weight reduction remains both effective and restorative
A provider who understands your context can help with appropriate dosing, timing, and monitoring that accounts for your activity level and nutritional demands
